Gossamer BiovsThermo Fisher Scientific

GOSS and TMO stock compared: price, dividend, valuation and results, from SEC filings.

TMO

Thermo Fisher Scientific Inc

$691.33

Value $257B

-1.27%
TMO's page

Gossamer Bio (GOSS) has a market value of $67M and Thermo Fisher Scientific (TMO) $257B. Over the last year, with dividends, GOSS moved -94.9% and TMO +19.9%. Dividend yield: GOSS none, TMO 0.27%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    GOSS$67M

    TMO$257B

    TMO is 3,824 times GOSS

  • Revenue, 12 months

    GOSS$78M

    TMO$47.4B

    TMO is 604 times GOSS

  • Net income, 12 months

    GOSS-$125M

    TMO$7.1B

  • Operating margin

    GOSS-140.0%

    TMO17.9%

    157.9 points apart

  • ROIC

    GOSS–

    TMO8.2%

  • P/E

    GOSS–

    TMO36.3

  • Dividend yield

    GOSS0.0%

    TMO0.3%

    0.3 points apart

  • 5-year return

    GOSS-98.8%

    TMO+10.9%

    109.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

GOSS-98.8%

TMO+10.9%

05010020222023202420252026
Returns by period
PeriodGOSSWith dividendsTMOWith dividends
1 year since November 14, 2025-94.9%Price -94.9%+19.9%Price +19.5%
3 years since November 16, 2023-83.4%-45.0% a yearPrice -83.4%+47.7%+13.9% a yearPrice +46.3%
5 years since November 15, 2021-98.8%-58.9% a yearPrice -98.8%+10.9%+2.1% a yearPrice +9.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

GOSSGossamer BioTMOThermo Fisher Scientific

Valuation

GOSSTMO
Valuation
Price$10.98$691.33
Market value$67M$257B
Enterprise value (EV)–$292B
P/E–36.3
P/E, 5-year median–32.7
P/B–4.7
EV/EBIT–34.5
Free cash flow yield–3.0%

Results and growth

GOSSTMO
Results and growth
Revenue, 12 months$78M$47.4B
Net income, 12 months-$125M$7.1B
Free cash flow, 12 months-$156M$7.6B
Earnings per share, 12 months-$0.53$18.96
Revenue growth, year on year-57.7%3.9%
Revenue growth a year, past–+6.7%over 5 years
EPS growth a year, past–+2.1%over 5 years

Margins and returns on capital

GOSSTMO
Margins and returns on capital
Gross margin––
Operating margin-140.0%17.9%
Net margin-159.5%14.9%
ROIC–8.2%
ROE–13.4%

Balance sheet

GOSSTMO
Balance sheet
Cash$51M$6.1B
Total debt–$41.4B
Net debt / EBITDA–3.7
Interest cover-10.3×5.5×

Dividends and buybacks

GOSSTMO
Dividends and buybacks
Dividend yield–0.3%
Dividend per share, 12 months–$1.84
Dividend growth a year, past–+14.3%over 5 years
Buyback yield–1.2%
Shareholder yield–1.4%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: GOSS or TMO

Didn't find what you were looking for?

Ask us
Which is bigger, Gossamer Bio or Thermo Fisher Scientific?

By market value, Thermo Fisher Scientific ($257B) is about 3,824.1 times Gossamer Bio ($67M), at today's prices.

How did GOSS and TMO stock do over the last 5 years?

Since November 15, 2021, GOSS's price moved -98.8% and TMO's +9.3%. With dividends: GOSS -98.8% (-58.9% a year), TMO +10.9% (+2.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, GOSS or TMO?

The dividend yield at today's price is none for Gossamer Bio and 0.27% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.

Which has the higher profit margins, Gossamer Bio or Thermo Fisher Scientific?

Over the last twelve months, the net margin was -159.5% for Gossamer Bio and 14.9% for Thermo Fisher Scientific, and the operating margin -140.0% and 17.9%. Revenue was $78M and $47.4B.

Which is the better investment, Gossamer Bio or Thermo Fisher Scientific?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.